Navigation Links
Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth
Date:4/29/2008

e financial performance, as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including Cynosure's history of operating losses, its reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, changes in consumer preferences, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K, which is filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward- looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.

Consolidated Statements of Income

(In thousands, except per share data)

Three Months Ended March 31,

2008 2007

(unaudited)

Revenues $36,763 $26,077

Cost of revenues 12,371 9,922

Gross profit 24,392 16,155

Operating expenses

Selling and marketing
'/>"/>

SOURCE Cynosure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Cynosure to Present at the Leerink Swann & Company/MEDACorp Aesthetics Roundtable Conference
2. Cynosure to Announce Fourth-Quarter and Full Year 2007 Financial Results on February 12
3. Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007
4. Cynosure Announces Upcoming Investor Presentations at Cowen and Citi Investor Conferences
5. Cynosure Introduces Smartlipo MPX(TM) Dual Wavelength Workstation for LaserBodySculpting(SM)
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. QMed, Inc. Reports July Medicare SNP Enrollments
8. Phlo Affiliate Reports Expanded Coverage to Oregon Border
9. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Carrington Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... a novel stem cell based,technology of Cellonis Biotechnologies, ... -- brain cancer -- of a 36 year ... treatment shows that the activated,immune system can directly ... daughter,cells. The amazing outcome of this novel treatment ... future vaccination therapies may be,targeted towards cancer stem ...
(Date:12/17/2009)... YORK, Dec. 17 Reportlinker.com announces ... available in its catalogue: ,, ... ,, http://www.reportlinker.com/p0170008/Infectious-Disease-Molecular-Diagnostic-Testing.html ... the clinical significance and market needs for ... listings of companies developing and marketing molecular ...
(Date:12/17/2009)... December 17 Biovista Inc.,today announced the ... access,to Biovista,s BEA literature mining platform. BEA will ... that Novus Biologicals is offering to visitors of ... allow site visitors to identify,genes that are related ... and from these browse Novus reagents that have ...
(Date:12/17/2009)... -- Osteotech, Inc. (Nasdaq: OSTE ), a ... for regenerative healing, announced today that it has ... Food and Drug Administration (FDA) to obtain marketing ... Matrix to repair or replace the dura mater ... cranial surgical procedures. This filing is based, ...
Breaking Biology Technology:For the First Time, a Glioma - Brain Cancer - may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 2For the First Time, a Glioma - Brain Cancer - may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 3For the First Time, a Glioma - Brain Cancer - may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 4Reportlinker Adds Infectious Disease Molecular Diagnostic Testing 2Novus Biologicals Awards Contract to Biovista Inc. to Drive its Web-Based Novus Explorer Service 2Osteotech Submits 510(k) Application to FDA for Clearance of its Duratech(TM) BioRegeneration Matrix 2Osteotech Submits 510(k) Application to FDA for Clearance of its Duratech(TM) BioRegeneration Matrix 3
... Aug. 5 Orexigen(R) Therapeutics,Inc. (Nasdaq: OREX ), ... system disorders, including obesity, will announce,financial results for its ... 2008, after the markets close. The announcement will be ... p.m. Pacific Time., Orexigen management will host the ...
... Innovations Inc.,(TSX: ATB), a recognized leading developer, manufacturer ... the health and,nutrition industries, today announced that its ... present a company overview,at the upcoming 28th Annual ... 2008 at 11 am (eastern time), in the ...
... NGSX ), a biopharmaceutical company focused on developing ... results for its second quarter 2008 on Wednesday, August ... to review the results will begin at 4:30 p.m. ... be hosted by Anthony DiTonno,President and Chief Executive Officer, ...
Other Biology Technology:Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008 2NeurogesX to Report Second Quarter 2008 Financial Results 2NeurogesX to Report Second Quarter 2008 Financial Results 3
(Date:12/17/2009)... Mark December 10-13, 2010 on your calendar and ... the International Osteoporosis Foundation (IOF). , IOF has ... of Regional Programs that aims to create strong ... member associations. The overall Regional Program includes the ... pleased to announce that the first IOF Regional ...
(Date:12/17/2009)... showing that four commonly used chemotherapy drugs disrupt the ... could be partially reversed with the growth factor IGF-1. ... Cancer Investigation , the University of Rochester Medical Center ... who experience a frustrating decline in cognitive function after ... is not yet clear how our results can be ...
(Date:12/17/2009)... Department of Energy,s Savannah River National Laboratory (SRNL) ... SRNL,s unique Porous Walled Hollow Glass Microspheres available ... and other uses, including applications still being developed. ... years in light-weight filler material, insulation, abrasives and ... unique is the network of interconnected pores in ...
Breaking Biology News(10 mins):UR study reveals chemo's toxicity to brain, possible treatment 2UR study reveals chemo's toxicity to brain, possible treatment 3MO-SCI Corporation to manufacture, market SRNL's unique glass microspheres 2SenesTech Announces New Vice President of Business Development 12862 1SenesTech Announces New Vice President of Business Development 12862 2Virginia Mason Signs with Carefx to Implement Fusionfx Solution Suite 50490 1Virginia Mason Signs with Carefx to Implement Fusionfx Solution Suite 50490 2Virginia Mason Signs with Carefx to Implement Fusionfx Solution Suite 50490 3Fighting Multiple Sclerosis One Shirt at a Time 50485 1Fighting Multiple Sclerosis One Shirt at a Time 50485 2
... CAMBRIDGE, Mass. (March 26, 2009) The Howard Hughes ... an Early Career Scientist appointment, a six-year funded position ... , "I am thrilled to receive the HHMI Early ... remarkable history of supporting innovative and creative science, and ...
... MARCH 2009 More than 120 researchers will speak ... life sciences conference to be organized by the European ... 29 August to 1 September 2009. , The ... programmes reflecting the concepts and high-resolution approaches of modern ...
... is available in Spanish . , ... of psychosis and schizophrenia, and those episodes of psychosis ... characteristics, both before their appearance and in the clinical ... conclusions of the doctoral thesis "Neurodevelopment and environmental stress ...
Other Biology News:Whitehead member Peter Reddien named HHMI Early Career Scientist 2Call for abstracts and registration for the EMBO Meeting 2009 2Daily consumption of cannabis predisposes to the appearance of psychosis and schizophrenia 2
Ras-related C3 botulinum toxin substrate 1...
Human sVCAM-1/CD106 ELI-PAIR Kit...
HP 1 alpha Immunogen: Synthetic peptide between amino acids 1-100 of the human HP 1 alpha protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... gene in baculoviral expression vector, transfection ... purification of ten clones, generation of ... clone, protein expression and tag purification ... yield and timeline: 1-4 mg of ...
Biology Products: